Latest Conference Articles

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

In this interview segment, Silverberg discussed some of the major takeaways from his Revolutionizing Atopic Dermatitis presentation on eligibility for systemic treatments.

An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.

Interim analysis suggest the JAK inhibitor may become a breakthrough treatment for chronic hand dermatitis—a condition currently without a marketed drug.

Post-hoc data from the phase 3 ADhere trial shows a lebrikizumab regimen may help patients with atopic dermatitis achieve skin clearance they could not with dupilumab.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

During this interview segment, Singh spoke on the ways in which dermatologists may help infants manage atopic dermatitis, as well as her outlook on the future of treatment.

A Brazil cross-sectional analysis suggests chronic pruritus is even more common—and burdensome—in atopic dermatitis patients than previously believed.

Eichenfield discussed his first presentation at the Revolutionizing Atopic Dermatitis conference, with his discussion covering systemic atopic dermatitis treatment for infants.

A new qualitative study of adults with atopic dermatitis shows preference for skin clearance, reduced risk of severe adverse events and a less frequent dosage.

New data show the novel investigative drug from Amytrx was associated with 37% improvement in atopic dermatitis body surface area.

Updated analysis of more than a dozen clinical trials assessing monotherapy systemic treatment of atopic dermatitis shows upadacitinib's highly prevalent efficacy in clearing skin.

At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.

At ARVO 2023, Goldberg discusses how dual Ang-2/VEGF inhibition can provide greater vascular stability, which may contribute to faster fluid resolution and extended durability with faricimab treatment.

A personalized treat-and-extend–based regimen presented at ARVO 2023 suggested the long-term potential of faricimab to reduce the treatment burden for patients with DME.

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

A posthoc analysis of the phase 2 CANDELA study presented at ARVO 2023 suggests aflibercept 8 mg improved visual and anatomical outcomes compared with aflibercept 2 mg in eyes with nAMD.

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

Presented at ARVO 2023, the nationwide data on nAMD real-world management in France suggest a discrepancy between avoiding the undertreatment of nAMD and the real-world management of the disease.

New research presented at ARVO 2023 suggests intravitreal brolucizumab led to the resolution of IRF and SRF in a significant number of patients with nAMD previously unresponsive to anti-VEGF therapy.

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.

Phase 3 results presented at ARVO 2023 suggest a switch from aflibercept to SB15 led to no treatment-emergent issues such as loss of efficacy, increased adverse events, or increased immunogenicity.

An analysis of the STATUS program suggests the percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing the IDx-DR system.

An analysis of the AlzEye study presented at ARVO 2023 suggests a deep-learning model showed promise in predicting three-year incident MACE using OCT.